select a format

Single User License
USD 2000 INR 128180
Site License
USD 4000 INR 256360
Corporate User License
USD 6000 INR 384540

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Bacterial Pneumonia-Pipeline Review, H1 2016

Bacterial Pneumonia-Pipeline Review, H1 2016


  • Products Id :- GMDHC8164IDB
  • |
  • Pages: 200
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Bacterial Pneumonia-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Bacterial Pneumonia-Pipeline Review, H1 2016', provides an overview of the Bacterial Pneumonia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bacterial Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Pneumonia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Bacterial Pneumonia

The report reviews pipeline therapeutics for Bacterial Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Bacterial Pneumonia therapeutics and enlists all their major and minor projects

The report assesses Bacterial Pneumonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Bacterial Pneumonia

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bacterial Pneumonia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bacterial Pneumonia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Bacterial Pneumonia Overview 9

Therapeutics Development 10

Pipeline Products for Bacterial Pneumonia-Overview 10

Pipeline Products for Bacterial Pneumonia-Comparative Analysis 11

Bacterial Pneumonia-Therapeutics under Development by Companies 12

Bacterial Pneumonia-Therapeutics under Investigation by Universities/Institutes 16

Bacterial Pneumonia-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Bacterial Pneumonia-Products under Development by Companies 21

Bacterial Pneumonia-Products under Investigation by Universities/Institutes 25

Bacterial Pneumonia-Companies Involved in Therapeutics Development 26

Abera Bioscience AB 26

Actelion Ltd 27

Alvogen Korea Co., Ltd. 28

Aridis Pharmaceuticals LLC 29

Arsanis Biosciences GmbH 30

AstraZeneca Plc 31

Beijing Minhai Biotechnology Co., Ltd 32

ContraFect Corporation 33

Daiichi Sankyo Company, Limited 34

Double Bond Pharmaceutical International AB 35

Emergent BioSolutions Inc. 36

Eurocine Vaccines AB 37

FluGen, Inc. 38

GlaxoSmithKline Plc 39

Humabs BioMed SA 40

ImmunoBiology Limited 41

Indian Immunologicals Limited 42

Integrated BioTherapeutics, Inc. 43

Kyorin Pharmaceutical Co., Ltd. 44

Lascco SA 45

LG Life Science LTD. 46

Liquidia Technologies, Inc. 47

MedImmune, LLC 48

Merck & Co., Inc. 49

Mucosis B.V. 50

Noxxon Pharma AG 51

Panacea Biotec Limited 52

Prometheon Pharma, LLC 53

Sanofi Pasteur SA 54

Serum Institute of India Limited 55

SK Chemicals Co., Ltd. 56

Sumitomo Dainippon Pharma Co., Ltd. 57

Valneva SE 58

Vaxxilon AG 59

Virometix AG 60

Walvax Biotechnology Co., Ltd. 61

Wellstat Vaccines, LLC 62

Wockhardt Limited 63

Bacterial Pneumonia-Therapeutics Assessment 64

Assessment by Monotherapy Products 64

Assessment by Combination Products 65

Assessment by Target 66

Assessment by Mechanism of Action 68

Assessment by Route of Administration 70

Assessment by Molecule Type 72

Drug Profiles 74

(cilastatin sodium + imipenem + relebactam)-Drug Profile 74

(Streptococcal pneumonia + typhoid) vaccine-Drug Profile 75

Ab-01-Drug Profile 76

ACT-292706-Drug Profile 77

ACT-387042-Drug Profile 78

Aerucin-Drug Profile 79

ASN-400-Drug Profile 81

AT-62aa-Drug Profile 82

AZ-6142-Drug Profile 84

CAL-02-Drug Profile 85

CB-027-Drug Profile 86

cefepime + zidebactam-Drug Profile 87

CF-301-Drug Profile 88

CF-302-Drug Profile 91

CF-303-Drug Profile 92

CF-309-Drug Profile 93

DEF-201-Drug Profile 94

doxycycline-Drug Profile 96

EV-035-Drug Profile 97

Fab-001-Drug Profile 99

GSK-2189242A-Drug Profile 100

KRPAM-1977X-Drug Profile 102

KRPAM-1977Y-Drug Profile 104

LBVE-Drug Profile 105

LCB-010371-Drug Profile 106

MEDI-3902-Drug Profile 107

Monoclonal Antibodies for Pneumococcus Infections-Drug Profile 108

Monoclonal Antibodies to Inhibit ADAM10 for Dermatology, Infectious Diseases and Respiratory Disorders-Drug Profile 109

Monoclonal Antibody for Staphylococcus Aureus Infections-Drug Profile 110

Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation and Neurodegenerative Diseases-Drug Profile 111

NBP-606-Drug Profile 112

NOXD-21-Drug Profile 113

Nucovac-Drug Profile 114

panobacumab-Drug Profile 115

PneuGEM-Drug Profile 117

pneumococcal (13-valent) vaccine-Drug Profile 118

pneumococcal (13-valent) vaccine-Drug Profile 119

pneumococcal (13-valent) vaccine-Drug Profile 120

pneumococcal (23-valent) vaccine-Drug Profile 121

pneumococcal (23-valent) vaccine-Drug Profile 122

pneumococcal [serotype 4, 6A] vaccine-Drug Profile 123

pneumococcal [strain TIGR4] vaccine-Drug Profile 124

pneumococcal vaccine-Drug Profile 125

pneumococcal vaccine-Drug Profile 126

pneumococcal vaccine-Drug Profile 127

pneumococcal vaccine-Drug Profile 128

pneumococcal vaccine-Drug Profile 129

pneumococcal vaccine-Drug Profile 130

pneumococcal vaccine-Drug Profile 131

pneumococcal vaccine-Drug Profile 133

pneumococcal vaccine-Drug Profile 134

PneumoMab-Drug Profile 135

pneumonia vaccine-Drug Profile 136

pneumonia vaccine-Drug Profile 137

pneumonia vaccine-Drug Profile 138

PnuBioVax-Drug Profile 139

PPV-23-Drug Profile 140

R-10001-Drug Profile 141

Recombinant Enzyme for Pseudomonas Aeruginosa Pneumonia-Drug Profile 142

SIILPCV-10-Drug Profile 143

SM-295291-Drug Profile 144

SM-369926-Drug Profile 145

Small Molecule for Respiratory Tract Infections-Drug Profile 146

Small Molecule to Inhibit CTP synthase for Respiratory Tract Infections-Drug Profile 147

Small Molecules for Chlamydophila Infections-Drug Profile 148

Small Molecules for Streptococcus Pneumoniae Infections-Drug Profile 149

Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections-Drug Profile 150

SRT-3025-Drug Profile 151

Staphylococcus aureus (multivalent) vaccine-Drug Profile 153

streptococcal pneumonia vaccine-Drug Profile 154

Streptococcal pneumonia vaccine-Drug Profile 155

Streptococcal pneumonia vaccine-Drug Profile 156

Streptococcal pneumonia vaccine 3-Drug Profile 157

Streptococcus pneumonia (whole-cell) vaccine-Drug Profile 158

Streptococcus pneumonia vaccine-Drug Profile 160

Streptococcus pneumonia vaccine-Drug Profile 161

Synthetic Peptides for Bacterial Infections-Drug Profile 162

tedizolid phosphate-Drug Profile 163

V-114-Drug Profile 170

VMT-1-Drug Profile 171

WCK-2349-Drug Profile 172

WCK-4873-Drug Profile 174

WCK-771-Drug Profile 175

Bacterial Pneumonia-Dormant Projects 176

Bacterial Pneumonia-Discontinued Products 182

Bacterial Pneumonia-Product Development Milestones 183

Featured News & Press Releases 183

Appendix 193

Methodology 193

Coverage 193

Secondary Research 193

Primary Research 193

Expert Panel Validation 193

Contact Us 193

Disclaimer 194

List of Figures

Number of Products under Development for Bacterial Pneumonia, H1 2016 16

Number of Products under Development for Bacterial Pneumonia-Comparative Analysis, H1 2016 17

Number of Products under Development by Companies, H1 2016 18

Number of Products under Investigation by Universities/Institutes, H1 2016 22

Comparative Analysis by Late Stage Development, H1 2016 23

Comparative Analysis by Clinical Stage Development, H1 2016 24

Comparative Analysis by Early Stage Products, H1 2016 25

Assessment by Monotherapy Products, H1 2016 70

Assessment by Combination Products, H1 2016 71

Number of Products by Top 10 Targets, H1 2016 72

Number of Products by Stage and Top 10 Targets, H1 2016 72

Number of Products by Top 10 Mechanism of Actions, H1 2016 74

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 74

Number of Products by Routes of Administration, H1 2016 76

Number of Products by Stage and Routes of Administration, H1 2016 76

Number of Products by Molecule Types, H1 2016 78

Number of Products by Stage and Molecule Types, H1 2016 78

List of Tables

Number of Products under Development for Bacterial Pneumonia, H1 2016 16

Number of Products under Development for Bacterial Pneumonia-Comparative Analysis, H1 2016 17

Number of Products under Development by Companies, H1 2016 19

Number of Products under Development by Companies, H1 2016 (Contd..1) 20

Number of Products under Development by Companies, H1 2016 (Contd..2) 21

Number of Products under Investigation by Universities/Institutes, H1 2016 22

Comparative Analysis by Late Stage Development, H1 2016 23

Comparative Analysis by Clinical Stage Development, H1 2016 24

Comparative Analysis by Early Stage Development, H1 2016 25

Comparative Analysis by Unknown Stage Development, H1 2016 26

Products under Development by Companies, H1 2016 27

Products under Development by Companies, H1 2016 (Contd..1) 28

Products under Development by Companies, H1 2016 (Contd..2) 29

Products under Development by Companies, H1 2016 (Contd..3) 30

Products under Investigation by Universities/Institutes, H1 2016 31

Bacterial Pneumonia-Pipeline by Abera Bioscience AB, H1 2016 32

Bacterial Pneumonia-Pipeline by Actelion Ltd, H1 2016 33

Bacterial Pneumonia-Pipeline by Alvogen Korea Co., Ltd., H1 2016 34

Bacterial Pneumonia-Pipeline by Aridis Pharmaceuticals LLC, H1 2016 35

Bacterial Pneumonia-Pipeline by Arsanis Biosciences GmbH, H1 2016 36

Bacterial Pneumonia-Pipeline by AstraZeneca Plc, H1 2016 37

Bacterial Pneumonia-Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 38

Bacterial Pneumonia-Pipeline by ContraFect Corporation, H1 2016 39

Bacterial Pneumonia-Pipeline by Daiichi Sankyo Company, Limited, H1 2016 40

Bacterial Pneumonia-Pipeline by Double Bond Pharmaceutical International AB, H1 2016 41

Bacterial Pneumonia-Pipeline by Emergent BioSolutions Inc., H1 2016 42

Bacterial Pneumonia-Pipeline by Eurocine Vaccines AB, H1 2016 43

Bacterial Pneumonia-Pipeline by FluGen, Inc., H1 2016 44

Bacterial Pneumonia-Pipeline by GlaxoSmithKline Plc, H1 2016 45

Bacterial Pneumonia-Pipeline by Humabs BioMed SA, H1 2016 46

Bacterial Pneumonia-Pipeline by ImmunoBiology Limited, H1 2016 47

Bacterial Pneumonia-Pipeline by Indian Immunologicals Limited, H1 2016 48

Bacterial Pneumonia-Pipeline by Integrated BioTherapeutics, Inc., H1 2016 49

Bacterial Pneumonia-Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 50

Bacterial Pneumonia-Pipeline by Lascco SA, H1 2016 51

Bacterial Pneumonia-Pipeline by LG Life Science LTD., H1 2016 52

Bacterial Pneumonia-Pipeline by Liquidia Technologies, Inc., H1 2016 53

Bacterial Pneumonia-Pipeline by MedImmune, LLC, H1 2016 54

Bacterial Pneumonia-Pipeline by Merck & Co., Inc., H1 2016 55

Bacterial Pneumonia-Pipeline by Mucosis B.V., H1 2016 56

Bacterial Pneumonia-Pipeline by Noxxon Pharma AG, H1 2016 57

Bacterial Pneumonia-Pipeline by Panacea Biotec Limited, H1 2016 58

Bacterial Pneumonia-Pipeline by Prometheon Pharma, LLC, H1 2016 59

Bacterial Pneumonia-Pipeline by Sanofi Pasteur SA, H1 2016 60

Bacterial Pneumonia-Pipeline by Serum Institute of India Limited, H1 2016 61

Bacterial Pneumonia-Pipeline by SK Chemicals Co., Ltd., H1 2016 62

Bacterial Pneumonia-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 63

Bacterial Pneumonia-Pipeline by Valneva SE, H1 2016 64

Bacterial Pneumonia-Pipeline by Vaxxilon AG, H1 2016 65

Bacterial Pneumonia-Pipeline by Virometix AG, H1 2016 66

Bacterial Pneumonia-Pipeline by Walvax Biotechnology Co., Ltd., H1 2016 67

Bacterial Pneumonia-Pipeline by Wellstat Vaccines, LLC, H1 2016 68

Bacterial Pneumonia-Pipeline by Wockhardt Limited, H1 2016 69

Assessment by Monotherapy Products, H1 2016 70

Assessment by Combination Products, H1 2016 71

Number of Products by Stage and Target, H1 2016 73

Number of Products by Stage and Mechanism of Action, H1 2016 75

Number of Products by Stage and Route of Administration, H1 2016 77

Number of Products by Stage and Molecule Type, H1 2016 79

Bacterial Pneumonia-Dormant Projects, H1 2016 182

Bacterial Pneumonia-Dormant Projects (Contd..1), H1 2016 183

Bacterial Pneumonia-Dormant Projects (Contd..2), H1 2016 184

Bacterial Pneumonia-Dormant Projects (Contd..3), H1 2016 185

Bacterial Pneumonia-Dormant Projects (Contd..4), H1 2016 186

Bacterial Pneumonia-Dormant Projects (Contd..5), H1 2016 187

Bacterial Pneumonia-Discontinued Products, H1 2016 188

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Abera Bioscience AB

Actelion Ltd

Alvogen Korea Co., Ltd.

Aridis Pharmaceuticals LLC

Arsanis Biosciences GmbH

AstraZeneca Plc

Beijing Minhai Biotechnology Co., Ltd

ContraFect Corporation

Daiichi Sankyo Company, Limited

Double Bond Pharmaceutical International AB

Emergent BioSolutions Inc.

Eurocine Vaccines AB

FluGen, Inc.

GlaxoSmithKline Plc

Humabs BioMed SA

ImmunoBiology Limited

Indian Immunologicals Limited

Integrated BioTherapeutics, Inc.

Kyorin Pharmaceutical Co., Ltd.

Lascco SA

LG Life Science LTD.

Liquidia Technologies, Inc.

MedImmune, LLC

Merck & Co., Inc.

Mucosis B.V.

Noxxon Pharma AG

Panacea Biotec Limited

Prometheon Pharma, LLC

Sanofi Pasteur SA

Serum Institute of India Limited

SK Chemicals Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Valneva SE

Vaxxilon AG

Virometix AG

Walvax Biotechnology Co., Ltd.

Wellstat Vaccines, LLC

Wockhardt Limited

Bacterial Pneumonia Therapeutic Products under Development, Key Players in Bacterial Pneumonia Therapeutics, Bacterial Pneumonia Pipeline Overview, Bacterial Pneumonia Pipeline, Bacterial Pneumonia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com